IDH1 and central nervous system cancer: As the earliest detectable genetic alteration in gliomagenesis, IDH1 heterozygous missense mutations in codon 132 cause an arginine-to-histidine substitution in 80–90 % of cases (R132H) [30] that leads to a distinct metabolism and hypermethylation phenotype in gliomas [31].